Decoding the Epitranscriptome: a New Frontier for Cancer Therapy and Drug Resistance

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2024 Oct 21

PMID 39434167

Authors

Lu Tang

Hua Tian

Qi Min

Huili You

Mengshuang Yin

Liqiong Yang

Yueshui Zhao

Xu Wu

Mingxing Li

Fukuan Du

Yu Chen

Shuai Deng

Xiaobing Li

Meijuan Chen

Li Gu

Yuhong Sun

Zhangang Xiao

Wanping Li

Jing Shen

Affiliations

Soon will be listed here.

Abstract

As the role of RNA modification in gene expression regulation and human diseases, the "epitranscriptome" has been shown to be an important player in regulating many physiological and pathological processes. Meanwhile, the phenomenon of cancer drug resistance is becoming more and more frequent, especially in the case of cancer chemotherapy resistance. In recent years, research on relationship between post-transcriptional modification and cancer including drug resistance has become a hot topic, especially the methylation of the sixth nitrogen site of RNA adenosine-mA (N6-methyladenosine). mA modification is the most common post-transcriptional modification of eukaryotic mRNA, accounting for 80% of RNA methylation modifications. At the same time, several other modifications of RNA, such as N1-methyladenosine (mA), 5-methylcytosine (mC), 3-methylcytosine (mC), pseudouridine (Ψ) and N7-methylguanosine (mG) have also been demonstrated to be involved in cancer and drug resistance. This review mainly discusses the research progress of RNA modifications in the field of cancer and drug resistance and targeting of mA regulators by small molecule modulators, providing reference for future study and development of combination therapy to reverse cancer drug resistance.

References

Eyler D, Franco M, Batool Z, Wu M, Dubuke M, Dobosz-Bartoszek M . Pseudouridinylation of mRNA coding sequences alters translation. Proc Natl Acad Sci U S A. 2019; 116(46):23068-23074. PMC: 6859337. DOI: 10.1073/pnas.1821754116. View

Wang X, Wong C, Chen H, Fu K, Shi L, Su H . The N-methyladenine DNA demethylase ALKBH1 promotes gastric carcinogenesis by disrupting NRF1 binding capacity. Cell Rep. 2023; 42(3):112279. DOI: 10.1016/j.celrep.2023.112279. View

Chen X, Li A, Sun B, Yang Y, Han Y, Yuan X . 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8):978-990. DOI: 10.1038/s41556-019-0361-y. View

Liang J, Cai H, Hou C, Song F, Jiang Y, Wang Z . METTL14 inhibits malignant progression of oral squamous cell carcinoma by targeting the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent manner. Clin Sci (Lond). 2023; 137(17):1373-1389. PMC: 10500204. DOI: 10.1042/CS20230219. View

Jin D, Guo J, Wu Y, Du J, Yang L, Wang X . mA mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2021; 14(1):32. PMC: 7901070. DOI: 10.1186/s13045-021-01048-8. View

Chen Y, Su H, Su Y, Zhang Y, Lin Y, Haglund F . Identification of an RNA-Binding-Protein-Based Prognostic Model for Ewing Sarcoma. Cancers (Basel). 2021; 13(15). PMC: 8345188. DOI: 10.3390/cancers13153736. View

Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X . Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. Cancer Res. 2023; 83(13):2187-2207. DOI: 10.1158/0008-5472.CAN-22-3059. View

Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K . AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017; 7:42271. PMC: 5304225. DOI: 10.1038/srep42271. View

Tooley J, Catlin J, Schaner Tooley C . METTLing in Stem Cell and Cancer Biology. Stem Cell Rev Rep. 2022; 19(1):76-91. PMC: 10563446. DOI: 10.1007/s12015-022-10444-7. View

10.

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

11.

Zhang X, Su T, Wu Y, Cai Y, Wang L, Liang C . N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression. Cancer Res. 2024; 84(6):827-840. DOI: 10.1158/0008-5472.CAN-23-1916. View

12.

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

13.

Gao W, Chen L, Lin L, Yang M, Li T, Wei H . SIAH1 reverses chemoresistance in epithelial ovarian cancer via ubiquitination of YBX-1. Oncogenesis. 2022; 11(1):13. PMC: 8913663. DOI: 10.1038/s41389-022-00387-6. View

14.

Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D . The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017; 551(7679):251-255. DOI: 10.1038/nature24456. View

15.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

16.

Song D, Guo M, Xu S, Song X, Bai B, Li Z . HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance. J Exp Clin Cancer Res. 2021; 40(1):170. PMC: 8120699. DOI: 10.1186/s13046-021-01951-5. View

17.

Xu L, Liu X, Sheng N, Oo K, Liang J, Chionh Y . Three distinct 3-methylcytidine (mC) methyltransferases modify tRNA and mRNA in mice and humans. J Biol Chem. 2017; 292(35):14695-14703. PMC: 5582859. DOI: 10.1074/jbc.M117.798298. View

18.

Zheng R, Yu Y, Lv L, Zhang Y, Deng H, Li J . mA reader HNRNPA2B1 destabilization of ATG4B regulates autophagic activity, proliferation and olaparib sensitivity in breast cancer. Exp Cell Res. 2023; 424(1):113487. DOI: 10.1016/j.yexcr.2023.113487. View

19.

Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J . ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021; 40(1):284. PMC: 8425158. DOI: 10.1186/s13046-021-02088-1. View

20.

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View